MDR requirements, devices and drugs that function together to achieve a specific medical purpose must be assessed comprehensively. The first regulatory aspect to consider is the classification of the device component. Medical devices are classified into risk categories (Class I, IIa, IIb, III) based on their intended use and the potential risks involved. Understanding these classifications will help identify the appropriate notified body involvement throughout the approval process.

In the context of drug-device combinations, one must not only consider the device aspects but also the pharmacological characteristics of the medicinal component. The overall classification and assessment will largely depend on whether the primary purpose of the product is as a medicinal product or a medical device.

Documentation requirements under the MDR necessitate the submission of a quality management system detailed as per ISO 13485 standards alongside compliance with Good Manufacturing Practice (GMP) for the drug component. Thus, it is vital to familiarize oneself with the General Safety and Performance Requirements (GSPR) outlined in Annex I of the EU MDR, as these will form the basis of the conformity assessment process.

Step 2: Dossier Preparation for Notified Body Submission

Once the regulatory framework is understood, the next crucial step involves preparing the necessary documentation for submission to the notified body. Dossier preparation should align with the requirements set forth in Annex II of the MDR, which dictates comprehensive evidence of safety and efficacy, risk management plans, and clinical evaluations specific to device–drug combinations.

The essential components that should be compiled in the technical documentation include:

• Device Description: A clear and detailed structure of the device, including design specifications, manufacturing processes, and its intended use within the treatment spectrum.
• Risk Management: A thorough risk analysis must be conducted in accordance with ISO 14971, detailing the identified risks associated with the device and accompanying medicinal product.
• Clinical Evaluation: This should include literature review and clinical trial data when available, supporting the safety and performance of the device in conjunction with the drug component.
• GSPR Compliance: Document how the device meets the GSPR as stipulated in the MDR.
• Post-market Surveillance Plan: A robust strategy detailing how the continued safety and effectiveness will be monitored post-approval.

Each of these components contributes to a comprehensive dossier that will be reviewed by the notified body. Engaging in iterative feedback sessions with the notified body prior to submission can often prove beneficial as it identifies potential gaps and helps streamline the assessment process.

Step 3: Notified Body Interaction and Assessment

Following the completion and submission of the technical documentation to a relevant notified body, the next phase involves interaction and assessment by the notified body. The selection of a notified body is critical, as not all bodies are authorized to assess specific combinations; ensure that the chosen notified body has the requisite expertise in both medical devices and pharmaceuticals.

Upon submission, the notified body will conduct a thorough review of the submitted dossier, which includes assessing the compliance of the device with the MDR. This assessment process encompasses document reviews and, at times, on-site evaluations. Detailed timelines and escalation routes should be established to maintain transparent communication throughout the process.

One significant aspect of the notified body assessment is their evaluation of the clinical data provided, solidifying the necessity of a solid clinical evaluation report. This documentation must align with the Clinical Evaluation Guidelines set by the Competent Authorities. In the case of inadequacies found during the review, the notified body may issue a request for additional information or clarification which must be addressed promptly.

Throughout the assessment phase, all communications with the notified body are vital to document comprehensively. Establishing clear objectives, timelines, and feedback loops will help manage expectations and foster a collaborative relationship.

Step 4: CE Marking and Regulatory Approval

Upon successfully navigating the assessment and resolution phases with the notified body, the next step is obtaining the CE marking, which signifies compliance with EU regulations. This marking is a declaration by the manufacturer that the product meets all regulatory requirements and can be marketed within the European Economic Area (EEA).

The CE marking process involves generating the Declaration of Conformity, wherein the manufacturer formally declares that the product conforms with the applicable legislation, including all relevant aspects of the MDR. It should summarize all evaluations conducted, including risk assessments and clinical assessments. Additionally, the following actions need to be undertaken:

• Liaise with EUDAMED: Prior to marketing, registration and compliance with the European Database on Medical Devices (EUDAMED) must be ensured, so product details are uploaded for transparency and regulatory oversight.
• Maintenance of Technical Documentation: Post-CE marking, ensure that technical documentation remains continuously updated to reflect any changes made in the product’s manufacturing or intended use.
• Market Launch Strategy: Develop comprehensive marketing strategies while ensuring compliance with local regulations on advertising for combination products.

It is necessary to maintain a vigilant post-marketing surveillance strategy in compliance with the MDR’s stringent requirements. This ensures continual monitoring of the device-drug combination’s performance and safety while also fulfilling the obligations set forth in any agreed post-market commitments.

Step 5: Ongoing Compliance and Vigilance

After securing market approval through CE marking, ongoing compliance and vigilance are paramount in the lifecycle management of device–drug combinations. Continuous monitoring of product performance both in clinical and post-market settings enables proactive identification of potential issues as part of the post-market surveillance plan.

This includes:

• Periodic Safety Update Reports (PSURs): Regular reports outlining the performance and safety profile of the product should be prepared and submitted to the relevant authorities, maintaining alignment with the agreed-upon post-market surveillance strategies.
• Adverse Event Reporting: Establish mechanisms to detect and report adverse events or unsafe usage of the product that may arise during its market lifecycle. Following up on these reports is essential to address issues promptly.
• Quality Management System Updates: Inclusion of feedback and data acquired from post-market evaluations helps refine manufacturing processes and quality assurance procedures.

Lastly, it is crucial to remain informed on regulatory changes and market dynamics that may affect the compliance status of the device-drug combination. Engaging in continuous education and consultations with regulatory experts and notified bodies are essential strategies to ensure that compliance is preserved in an ever-evolving regulatory landscape.

This comprehensive tutorial provides guidance on the procedural steps for conducting a successful MDR conformity assessment process for device–drug combinations. By closely adhering to the recommended actions, companies can ensure the development of safe and effective products while maintaining compliance with both EU MDR and US regulations.